{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:04:28Z","timestamp":1792591468998,"version":"4.5.0"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.yebeh.2022.108577","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T12:40:06Z","timestamp":1644410406000},"page":"108577","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["A scoping review on cannabidiol therapy in tuberous sclerosis: Current evidence and perspectives for future development"],"prefix":"10.1016","volume":"128","author":[{"given":"Debopam","family":"Samanta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2022.108577_b0005","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMra055323","article-title":"The tuberous sclerosis complex","volume":"355","author":"Crino","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.yebeh.2022.108577_b0010","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1177\/08830738040190090801","article-title":"Managing epilepsy in tuberous sclerosis complex","volume":"19","author":"Thiele","year":"2004","journal-title":"J Child Neurol"},{"issue":"5","key":"10.1016\/j.yebeh.2022.108577_b0015","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ejpn.2018.05.006","article-title":"Management of epilepsy associated with tuberous sclerosis complex: updated clinical recommendations","volume":"22","author":"Curatolo","year":"2018","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2022.108577_b0020","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pediatrneurol.2021.07.011","article-title":"Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations","volume":"123","author":"Northrup","year":"2021","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2022.108577_b0025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.pediatrneurol.2020.03.008","article-title":"An updated review of tuberous sclerosis complex-associated autism spectrum disorder","volume":"109","author":"Samanta","year":"2020","journal-title":"Pediatr Neurol"},{"issue":"20","key":"10.1016\/j.yebeh.2022.108577_b0030","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.yebeh.2022.108577_b0035","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.yebeh.2022.108577_b0040","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/epi.12631","article-title":"Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders","volume":"55","author":"Devinsky","year":"2014","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.yebeh.2022.108577_b0045","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1056\/NEJMra1407304","article-title":"Cannabinoids in the treatment of epilepsy","volume":"373","author":"Longo","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2022.108577_b0050","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pediatrneurol.2019.03.014","article-title":"Cannabidiol: A review of clinical efficacy and safety in epilepsy","volume":"96","author":"Samanta","year":"2019","journal-title":"Pediatr Neurol"},{"issue":"10","key":"10.1016\/j.yebeh.2022.108577_b0055","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s40263-018-0558-9","article-title":"Efficacy and safety of adjunctive cannabidiol in patients with lennox-gastaut syndrome: A systematic review and meta-analysis","volume":"32","author":"Lattanzi","year":"2018","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.yebeh.2022.108577_b0060","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamaneurol.2020.0073","article-title":"Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial","volume":"77","author":"Miller","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2022.108577_b0065","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.yebeh.2022.108577_b0070","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jamaneurol.2020.4607","article-title":"Add-On cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: A placebo-controlled randomized clinical trial","volume":"78","author":"Thiele","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2022.108577_b0075","article-title":"Long-term safety and efficacy of cannabidiol (CBD) for the treatment of seizures in patients with tuberous sclerosis complex (TSC) in an open-label extension (OLE) trial (GWPCARE6)(677)","author":"Thiele","year":"2020","journal-title":"AAN Enterprises"},{"issue":"8","key":"10.1016\/j.yebeh.2022.108577_b0080","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/epi.13060","article-title":"Drug\u2013drug interaction between clobazam and cannabidiol in children with refractory epilepsy","volume":"56","author":"Geffrey","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108577_b0085","doi-asserted-by":"crossref","first-page":"106988","DOI":"10.1016\/j.yebeh.2020.106988","article-title":"Cannabidiol in treatment of refractory epileptic spasms: An open-label study","volume":"106","author":"Herlopian","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108577_b0090","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/epi.13499","article-title":"Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex","volume":"57","author":"Hess","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108577_b0095","doi-asserted-by":"crossref","first-page":"106263","DOI":"10.1016\/j.eplepsyres.2019.106263","article-title":"Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam","volume":"160","author":"Savage","year":"2020","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108577_b0100","article-title":"Long-term efficacy and safety of cannabidiol (CBD) in patients with tuberous sclerosis complex (TSC): 4-year results from the expanded access program (EAP) (2405)","author":"Weinstock","year":"2021","journal-title":"AAN Enterprises"},{"key":"10.1016\/j.yebeh.2022.108577_b0105","doi-asserted-by":"crossref","unstructured":"Saneto R, Sparagana S, Kwan P, O\u2019Callaghan F, Wheless J, Hyland K, et al. Efficacy of add-on cannabidiol (CBD) treatment in patients with tuberous sclerosis complex (TSC) and a history of infantile spasms (IS): post hoc analysis of phase 3 trial GWPCARE6 (1534). AAN Enterprises; 2021.","DOI":"10.1212\/WNL.96.15_supplement.1534"},{"key":"10.1016\/j.yebeh.2022.108577_b0110","doi-asserted-by":"crossref","unstructured":"Wheless J, Bebin EM, Filloux F, Kwan P, Jansen FE, Loftus R, et al. Long-term safety and efficacy of add-on cannabidiol (CBD) for treatment of seizures associated with tuberous sclerosis complex (TSC) in an open-label extension (OLE) trial (GWPCARE6)(1127). AAN Enterprises; 2021.","DOI":"10.1212\/WNL.96.15_supplement.1127"},{"issue":"7","key":"10.1016\/j.yebeh.2022.108577_b0115","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/epi.16936","article-title":"The long-term efficacy of cannabidiol in the treatment of refractory epilepsy","volume":"62","author":"Patel","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108577_b0120","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pediatrneurol.2019.11.017","article-title":"Cannabidiol elevates mechanistic target of rapamycin inhibitor levels in patients with tuberous sclerosis complex","volume":"105","author":"Ebrahimi-Fakhari","year":"2020","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2022.108577_b0125","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/978-3-319-20825-1_10","article-title":"Cannabis and endocannabinoid signaling in epilepsy","author":"Katona","year":"2015","journal-title":"Endocannabinoids"},{"key":"10.1016\/j.yebeh.2022.108577_b0130","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.yebeh.2016.11.016","article-title":"Pharmacology of cannabinoids in the treatment of epilepsy","volume":"70","author":"Gaston","year":"2017","journal-title":"Epilepsy Behav"},{"issue":"4","key":"10.1016\/j.yebeh.2022.108577_b0135","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide","volume":"134","author":"Bisogno","year":"2001","journal-title":"Br J Pharmacol"},{"issue":"20","key":"10.1016\/j.yebeh.2022.108577_b0140","doi-asserted-by":"crossref","first-page":"7895","DOI":"10.1073\/pnas.0511232103","article-title":"Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression","volume":"103","author":"Carrier","year":"2006","journal-title":"Proc Natl Acad Sci"},{"issue":"7","key":"10.1016\/j.yebeh.2022.108577_b0145","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","article-title":"Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes","volume":"163","author":"De Petrocellis","year":"2011","journal-title":"Br J Pharmacol"},{"issue":"1-3","key":"10.1016\/j.yebeh.2022.108577_b0150","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejphar.2011.01.013","article-title":"Cannabinoids inhibit the synaptic uptake of adenosine and dopamine in the rat and mouse striatum","volume":"655","author":"Pandolfo","year":"2011","journal-title":"Eur J Pharmacol"},{"issue":"13","key":"10.1016\/j.yebeh.2022.108577_b0155","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s40265-019-01171-4","article-title":"Pharmacological and therapeutic properties of cannabidiol for epilepsy","volume":"79","author":"Franco","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.yebeh.2022.108577_b0160","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.neuro.2015.08.007","article-title":"Cannabidiol, a Cannabis sativa constituent, inhibits cocaine-induced seizures in mice: possible role of the mTOR pathway and reduction in glutamate release","volume":"50","author":"Gobira","year":"2015","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.yebeh.2022.108577_b0165","doi-asserted-by":"crossref","first-page":"104553","DOI":"10.1016\/j.fitote.2020.104553","article-title":"Cannabidiol exerts protective effects in an in vitro model of Parkinson\u2019s disease activating AKT\/mTOR pathway","volume":"143","author":"Gugliandolo","year":"2020","journal-title":"Fitoterapia"},{"key":"10.1016\/j.yebeh.2022.108577_b0170","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbr.2019.01.040","article-title":"Cannabidiol modulates phosphorylated rpS6 signalling in a zebrafish model of tuberous sclerosis complex","volume":"363","author":"Serra","year":"2019","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.yebeh.2022.108577_b0175","article-title":"Time to onset of cannabidiol (CBD) treatment effect and resolution of adverse events (AEs) in the tuberous sclerosis complex (TSC) phase 3 randomized controlled trial (GWPCARE6)(674)","author":"Wu","year":"2020","journal-title":"AAN Enterprises"},{"issue":"7","key":"10.1016\/j.yebeh.2022.108577_b0180","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0387-7604(01)00300-X","article-title":"Infantile spasms in tuberous sclerosis complex","volume":"23","author":"Curatolo","year":"2001","journal-title":"Brain Dev"},{"key":"10.1016\/j.yebeh.2022.108577_b0185","doi-asserted-by":"crossref","first-page":"106826","DOI":"10.1016\/j.yebeh.2019.106826","article-title":"Synthetic pharmaceutical grade cannabidiol for treatment of refractory infantile spasms: A multicenter phase-2 study","volume":"102","author":"Hussain","year":"2020","journal-title":"Epilepsy Behav"},{"issue":"1","key":"10.1016\/j.yebeh.2022.108577_b0190","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pediatrneurol.2014.10.004","article-title":"Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist","volume":"52","author":"de Vries","year":"2015","journal-title":"Pediatr Neurol"},{"issue":"1","key":"10.1016\/j.yebeh.2022.108577_b0195","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-018-0901-8","article-title":"TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study","volume":"13","author":"de Vries","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.1016\/j.yebeh.2022.108577_b0200","doi-asserted-by":"crossref","first-page":"e00682","DOI":"10.1002\/prp2.682","article-title":"Diversity of molecular targets and signaling pathways for CBD","volume":"8","author":"Almeida","year":"2020","journal-title":"Pharmacol Res Perspect"},{"issue":"8","key":"10.1016\/j.yebeh.2022.108577_b0205","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic properties of cannabidiol at 5-HT1a receptors","volume":"30","author":"Russo","year":"2005","journal-title":"Neurochem Res"},{"issue":"13","key":"10.1016\/j.yebeh.2022.108577_b0210","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/j.cgh.2015.06.020","article-title":"Risk of acute liver failure in patients with drug-induced liver injury: evaluation of Hy\u2019s law and a new prognostic model","volume":"13","author":"Lo Re","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.yebeh.2022.108577_b0215","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3389\/fneur.2020.00829","article-title":"Slow titration of cannabidiol add-on in drug-resistant epilepsies can improve safety with maintained efficacy in an open-label study","volume":"11","author":"D'Onofrio","year":"2020","journal-title":"Front Neurol"},{"issue":"8","key":"10.1016\/j.yebeh.2022.108577_b0220","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/cpdd.665","article-title":"A phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects","volume":"8","author":"Morrison","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"6","key":"10.1016\/j.yebeh.2022.108577_b0225","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/epi.16542","article-title":"Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials","volume":"61","author":"Bialer","year":"2020","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.yebeh.2022.108577_b0230","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/bcp.14158","article-title":"Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop-seizure frequency","volume":"86","author":"Bergmann","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"06","key":"10.1016\/j.yebeh.2022.108577_b0235","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1055\/s-0039-1695786","article-title":"Cannabidiol interacts significantly with everolimus\u2014report of a patient with tuberous sclerosis complex","volume":"50","author":"Wiemer-Kruel","year":"2019","journal-title":"Neuropediatrics"},{"issue":"9","key":"10.1016\/j.yebeh.2022.108577_b0240","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/epi.13852","article-title":"Interactions between cannabidiol and commonly used antiepileptic drugs","volume":"58","author":"Gaston","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108577_b0245","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.yebeh.2019.07.008","article-title":"Drug\u2013drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program","volume":"98","author":"Gaston","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108577_b0250","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1111\/epi.16071","article-title":"Effects of cannabidiol on brivaracetam plasma levels","volume":"60","author":"Klotz","year":"2019","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.yebeh.2022.108577_b0255","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/08830738060210011201","article-title":"Levetiracetam as adjunctive antiepileptic therapy for patients with tuberous sclerosis complex: a retrospective open-label trial","volume":"21","author":"Collins","year":"2006","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2022.108577_b0260","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.697467","article-title":"Historical patterns of diagnosis, treatments, and outcome of epilepsy associated with tuberous sclerosis complex: results from TOSCA registry","volume":"12","author":"Nabbout","year":"2021","journal-title":"Front Neurol"},{"issue":"6","key":"10.1016\/j.yebeh.2022.108577_b0265","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1007\/s00415-017-8507-y","article-title":"Long-term outcomes of epilepsy surgery in tuberous sclerosis complex","volume":"264","author":"Liang","year":"2017","journal-title":"J Neurol"},{"issue":"8","key":"10.1016\/j.yebeh.2022.108577_b0270","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/j.1528-1167.2007.01117.x","article-title":"Epilepsy surgery in tuberous sclerosis: a systematic review","volume":"48","author":"Jansen","year":"2007","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.yebeh.2022.108577_b0275","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ejpn.2012.05.004","article-title":"Management of epilepsy associated with tuberous sclerosis complex (TSC): clinical recommendations","volume":"16","author":"Curatolo","year":"2012","journal-title":"Eur J Paediatr Neurol"},{"issue":"1","key":"10.1016\/j.yebeh.2022.108577_b0280","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/epi4.12286","article-title":"Epilepsy in tuberous sclerosis complex: findings from the TOSCA Study","volume":"4","author":"Nabbout","year":"2019","journal-title":"Epilepsia Open"},{"issue":"5","key":"10.1016\/j.yebeh.2022.108577_b0285","doi-asserted-by":"crossref","first-page":"260","DOI":"10.5698\/1535-7511-15.5.260","article-title":"Seeking the rational (or at least avoiding the irrational) rational polypharmacy in practice","volume":"15","author":"Gidal","year":"2015","journal-title":"Epilepsy Curr"},{"issue":"8","key":"10.1016\/j.yebeh.2022.108577_b0290","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/jamaneurol.2014.808","article-title":"Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action","volume":"71","author":"Margolis","year":"2014","journal-title":"JAMA Neurol"},{"issue":"10","key":"10.1016\/j.yebeh.2022.108577_b0295","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1111\/j.1528-1167.2005.00266.x","article-title":"Tuberous sclerosis complex and the ketogenic diet","volume":"46","author":"Kossoff","year":"2005","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.yebeh.2022.108577_b0300","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1111\/epi.16610","article-title":"A pragmatic algorithm to select appropriate antiseizure medications in patients with epilepsy","volume":"61","author":"Asadi\u2010Pooya","year":"2020","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.yebeh.2022.108577_b0305","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1528-1157.1998.tb01268.x","article-title":"Antiepileptic drugs as a cause of worsening seizures","volume":"39","author":"Perucca","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108577_b0310","doi-asserted-by":"crossref","unstructured":"Roebuck AJ, Greba Q, Onofrychuk TJ, McElroy DL, Sandini TM, Zagzoog A, et al. Dissociable changes in spike and wave discharges following exposure to injected cannabinoids and smoked cannabis in Genetic Absence Epilepsy Rats from Strasbourg. Eur J Neurosci 2020.","DOI":"10.1111\/ejn.15096"},{"key":"10.1016\/j.yebeh.2022.108577_b0315","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.yebeh.2018.07.020","article-title":"Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study","volume":"87","author":"Szaflarski","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108577_b0320","doi-asserted-by":"crossref","first-page":"107862","DOI":"10.1016\/j.yebeh.2021.107862","article-title":"Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy","volume":"117","author":"Gaston","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"42","key":"10.1016\/j.yebeh.2022.108577_b0325","doi-asserted-by":"crossref","first-page":"11229","DOI":"10.1073\/pnas.1711351114","article-title":"Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome","volume":"114","author":"Kaplan","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.yebeh.2022.108577_b0330","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1089\/can.2019.0005","article-title":"Cannabidiol-enriched extract reduced the cognitive impairment but not the epileptic seizures in a lafora disease animal model","volume":"5","author":"Aso","year":"2020","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.yebeh.2022.108577_b0335","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3389\/fphar.2017.00131","article-title":"Protective effects of cannabidiol against seizures and neuronal death in a rat model of mesial temporal lobe epilepsy","volume":"8","author":"Do Val-da Silva","year":"2017","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.yebeh.2022.108577_b0340","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/epi.14629","article-title":"Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models","volume":"60","author":"Patra","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108577_b0345","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.yebeh.2019.04.008","article-title":"fMRI study of cannabidiol-induced changes in attention control in treatment-resistant epilepsy","volume":"96","author":"Allendorfer","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108577_b0350","doi-asserted-by":"crossref","first-page":"108325","DOI":"10.1016\/j.yebeh.2021.108325","article-title":"Seizure frequency, quality of life, behavior, cognition, and sleep in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol","volume":"124","author":"Anderson","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108577_b0355","doi-asserted-by":"crossref","first-page":"107558","DOI":"10.1016\/j.yebeh.2020.107558","article-title":"Cognitive and behavioral effects of cannabidiol in patients with treatment-resistant epilepsy","volume":"114","author":"Metternich","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"9","key":"10.1016\/j.yebeh.2022.108577_b0360","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.neubiorev.2012.07.005","article-title":"GABA system dysfunction in autism and related disorders: from synapse to symptoms","volume":"36","author":"Coghlan","year":"2012","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.yebeh.2022.108577_b0365","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.brainres.2009.09.120","article-title":"Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders","volume":"1309","author":"Hutsler","year":"2010","journal-title":"Brain Res"},{"key":"10.1016\/j.yebeh.2022.108577_b0370","doi-asserted-by":"crossref","first-page":"11300","DOI":"10.1523\/JNEUROSCI.2270-05.2005","article-title":"Control of dendritic arborization by the phosphoinositide-3\u2019-kinase-Akt-mammalian target of rapamycin pathway","volume":"25","author":"Jaworski","year":"2005","journal-title":"JNeurosci"},{"key":"10.1016\/j.yebeh.2022.108577_b0375","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/ddrr.118","article-title":"Managing irritability and aggression in autism spectrum disorders in children and adolescents","volume":"16","author":"Robb","year":"2010","journal-title":"Dev Disabil Res Rev"},{"issue":"12","key":"10.1016\/j.yebeh.2022.108577_b0380","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1080\/14656566.2019.1626825","article-title":"Aripiprazole for treating irritability associated with autism spectrum disorders","volume":"20","author":"Bartram","year":"2019","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"10.1016\/j.yebeh.2022.108577_b0385","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s10803-018-3808-2","article-title":"Brief report: cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems\u2014a retrospective feasibility study","volume":"49","author":"Aran","year":"2019","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.yebeh.2022.108577_b0390","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3389\/fphar.2018.01521","article-title":"Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and comorbidities","volume":"9","author":"Barchel","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.yebeh.2022.108577_b0395","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3389\/fneur.2019.01145","article-title":"Effects of CBD-enriched cannabis sativa extract on autism spectrum disorder symptoms: an observational study of 18 participants undergoing compassionate use","volume":"10","author":"Fleury-Teixeira","year":"2019","journal-title":"Front Neurol"},{"key":"10.1016\/j.yebeh.2022.108577_b0400","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.jns.2017.08.2623","article-title":"Oral cannabis extracts as a promising treatment for the core symptoms of autism spectrum disorder: preliminary experience in chilean patients","volume":"381","author":"Kuester","year":"2017","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.yebeh.2022.108577_b0405","doi-asserted-by":"crossref","unstructured":"McVige J, Headd V, Alwahaidy M, Lis D, Kaur D, Albert B, et al. Medical cannabis in the treatment of patients with autism spectrum disorder (1648). AAN Enterprises; 2020.","DOI":"10.1212\/WNL.94.15_supplement.1648"},{"key":"10.1016\/j.yebeh.2022.108577_b0410","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41598-018-37570-y","article-title":"Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy","volume":"9","author":"Bar-Lev Schleider","year":"2019","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.yebeh.2022.108577_b0415","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1177\/0883073812465122","article-title":"Atypical face processing in children with tuberous sclerosis complex","volume":"28","author":"Jeste","year":"2013","journal-title":"J Child Neurol"},{"issue":"9","key":"10.1016\/j.yebeh.2022.108577_b0420","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1177\/0269881119858306","article-title":"The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD)","volume":"33","author":"Pretzsch","year":"2019","journal-title":"J Psychopharmacol"},{"issue":"7","key":"10.1016\/j.yebeh.2022.108577_b0425","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1212\/WNL.0b013e3182a08f3f","article-title":"\u03b1-[11C]-Methyl-L-tryptophan\u2013PET in 191 patients with tuberous sclerosis complex","volume":"81","author":"Chugani","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108577_b0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.pediatrneurol.2019.07.008","article-title":"Preventive antiepileptic treatment in tuberous sclerosis complex: long-term, prospective trial","author":"Jozwiak","year":"2019","journal-title":"Pediatr Neurol"},{"issue":"5","key":"10.1016\/j.yebeh.2022.108577_b0435","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejpn.2011.03.010","article-title":"Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex","volume":"15","author":"J\u00f3\u017awiak","year":"2011","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2022.108577_b0440","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.25956","article-title":"Prevention of epilepsy in infants with tuberous sclerosis complex in the EPISTOP trial","volume":"89","author":"Kotulska","year":"2021","journal-title":"Ann Neurol"},{"issue":"24","key":"10.1016\/j.yebeh.2022.108577_b0445","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1212\/WNL.0000000000001069","article-title":"Vigabatrin retinal toxicity in children with infantile spasms: an observational cohort study","volume":"83","author":"Westall","year":"2014","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.yebeh.2022.108577_b0450","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1212\/WNL.0000000000007749","article-title":"A randomized controlled trial with everolimus for IQ and autism in tuberous sclerosis complex","volume":"93","author":"Overwater","year":"2019","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.yebeh.2022.108577_b0455","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s40263-021-00867-0","article-title":"Effect of cannabidiol on interictal epileptiform activity and sleep architecture in children with intractable epilepsy: A prospective open-label study","volume":"35","author":"Klotz","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2022.108577_b0460","doi-asserted-by":"crossref","first-page":"107837","DOI":"10.1016\/j.yebeh.2021.107837","article-title":"Underutilization of epilepsy surgery: Part I: A scoping review of barriers","volume":"117","author":"Samanta","year":"2021","journal-title":"Epilepsy Behav"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022000269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022000269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:46:05Z","timestamp":1761504365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505022000269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":92,"alternative-id":["S1525505022000269"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.108577","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A scoping review on cannabidiol therapy in tuberous sclerosis: Current evidence and perspectives for future development","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.108577","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108577"}}